(12) **Translation of European patent specification**

(11) **NO/EP 2985032 B1**

NORWAY

(19) NO

(51) Int Cl.

A61K 38/10 (2006.01)
A61P 25/22 (2006.01)
A61P 25/24 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.06.17
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.01.02
(86)	European Application Nr.	15171991.1
(86)	European Filing Date	2010.10.05
(87)	The European Application's Publication Date	2016.02.17
(30)	Priority	2009.10.05, US, 248650 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Northwestern University, 633 Clark Street, Evanston, IL 60208, USA
(72)	Inventor	MOSKAL, Joseph, 801 Central Street, Evanston, IL Illinois 60201, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **GLYX FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR HUNTINGTON'S DISEASE**

(56) References Cited:

WO-A2-02/072609

BURGDORF JEFFREY ET AL: "The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats", NEUROBIOLOGY OF AGING, USA, vol. 32, no. 4, 1 April 2011 (2011-04-01), pages 698-706, XP009166613, ISSN: 1558-1497, DOI: 10.1016/J.NEUROBIOLAGING.2009.04.012

WOLFRAM-ADUAN A ET AL: "Globus pallidus neurochemical responses to the partial NMDA agonist GLYX-13 among HD51(CAG) Huntington's disease model rats", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 41, 1 January 2011 (2011-01-01), XP009166606, ISSN: 0190-5295

KRYSTAL J H ET AL: "NMDA AGONISTS AND ANTAGONISTS AS PROBES OF GLUTAMATERGIC DYSFUNCTION AND PHARMACOTHERAPIES IN NEUROPSYCHIATRIC DISORDERS", HARVARD REVIEW OF PSYCHIATRY, ST. LOUIS, MO, US, vol. 7, no. 3, 1 January 1999 (1999-01-01) , pages 125-143, XP008048548, ISSN: 1067-3229, DOI: 10.1093/HRP/7.3.125

MOSKAL J R ET AL: "GLYX-13: A monoclonal antibody-derived peptide that acts as an N-

methyl-d-aspartate receptor modulator", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 49, no. 7, 1 December 2005 (2005-12-01), pages 1077-1087, XP027632781, ISSN: 0028-3908 [retrieved on 2005-12-01]
CRANE A ET AL: "Reduction of cognitive deficits in the HD 51 CAG rat model of Huntington's disease with a NMDA receptor partial agonist, GLYX-13", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 41, 14 November 2011 (2011-11-14), XP009166597, ISSN: 0190-5295
ZHANG X L ET AL: "A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 55, no. 7, 1 December 2008 (2008-12-01), pages 1238-1250, XP025585049, ISSN: 0028-3908, DOI: 10.1016/J.NEUROPHARM.2008.08.018 [retrieved on 2008-08-29]
STANTON PATRIC K ET AL: "Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13", NEUROREPORT, LIPPINCOTT WILLIAMS & WILKINS, UK, vol. 20, no. 13, 1 August 2009 (2009-08-01), pages 1193-1197, XP009166611, ISSN: 0959-4965, DOI: 10.1097/WNR.0B013E32832F5130

PATENTKRAV

1. GLYX-peptid for anvendelse i en fremgangsmåte for behandling av en pasient som lider av Alzheimers sykdom, Parkinsons sykdom eller Huntingtons sykdom, hvor GLYX-peptidet er GLYX-13 som har strukturen med formel I:



Formel I

2. GLYX-peptid for anvendelse ifølge krav 1, hvori fremgangsmåten er for behandling av Alzheimers sykdom, Parkinsons sykdom eller Huntingtons sykdom hos pattedyr inkludert mennesker.